The Interaction of Immunosuppressive Compos in Tandem Stimulated Eripheral Human Lymphocytes

References

• Sollinger H. W., Deierhoi M. H., Belzer F. O., Diethelm A. G., Kauffman R. S. RS-61443-a phase I clinical trial and pilot rescue study. Transplantation 1992; 53: 428
   PubMed Web of Science ®Google Scholar
• Shenoy M., MacPherson B., Christadoss P. Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production. Journal of Clinical Immunology 1992; 12: 122
   PubMed Web of Science ®Google Scholar
• Boiling S. F., Kunkel S. L., Lin H. Prolongation of cardiac allograft survival in rats by anti-TNF and cyclosporine combination therapy. Transplantation 1992; 53: 283
   PubMedGoogle Scholar
• Cramer D. V., Chapman F. A., Jaffee B. D., Jones E. A., Knoop M., Hreha-Eiras G., Makowka L. The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat. Transplantation 1992; 53: 303
   PubMed Web of Science ®Google Scholar
• Wanders A., Tufveson G., Gerdin B. Enhancement of the effect of lowdose cyclosporin A by sulphsalazine in prevention of cardiac allograft rejection in the rat. Transplantation International 1992; 5: 155
   PubMedGoogle Scholar
• Nemoto K., Sugawara Y., Mae M., Hayashi M., Abe F., Fujii A., Takeuchi T. Therapeutic activity of deoxyspergualin in comparison with cyclosporin A, and its combined use with cyclosporin A and prednisolone in highly allogeneic skin transplantation in the rat. Agents-Actions 1992; 36: 306
   PubMedGoogle Scholar
• Hibbins M., Chapman J. R. In vitro assesment of triple-therapy immunosuppression and prostaglandin analogues Enisoprost and Misoprostol. Transplantation Proceedings 1992; 24: 224
   PubMedGoogle Scholar
• Takano Y., Takahara S., Jiang H., Kokado Y., Kameoka H., Moutabarrik A., Ishibashi M., Okuyama A. Immunosuppressive mechanism of action of deoxymethylspergualin - A human in vitro assay. Transplantation Proceedings 1992; 24: 1372
   PubMedGoogle Scholar
• Weaver J. L., Pine P. S., Aszalos A. Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. Immunopharmacology and Immunotoxicology 1991; 13: 563
   PubMed Web of Science ®Google Scholar
• Koulova L, Clark E. A., Shu G., Dupont B. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ cells. Journal of Experimental Medicine 1991; 173: 759
   PubMed Web of Science ®Google Scholar
• Dumont F. J., Staruch M. J., Koprak S. L., Melino M. R., Sigal N. H. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. Journal of Immunology 1990; 144: 251
   PubMed Web of Science ®Google Scholar
• Andersson J., Nagy S., Groth C. G., Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single cell level. Immunology 1992; 75: 136
   PubMed Web of Science ®Google Scholar
• Dumont F. J., Melino M. R., Staruch M. J., Koprak S. L., Fischer P. A., Sigal N. H. The immunosuppresive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. Journal of Immunology 1990; 144: 1418
   PubMed Web of Science ®Google Scholar
• Heitman J., Movva N. R., Hall M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253: 905
   PubMed Web of Science ®Google Scholar
• Price D. J., Grove J. R., Calvo V., Avruch J., Bierer B. E. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992; 257: 973
   PubMed Web of Science ®Google Scholar
• Hodges S. D., Fung E., McKay D. J., Renaux B. S., Snyder F. F. Increased activity, amount, and altered kinetic properties of IMP dehydrogenase from mycophenolic acid-resistant neuroblastoma cells. Journal of Biological Chemistry 1989; 264: 18137
   PubMedGoogle Scholar
• Eugui E. M., Asmquist S. J., Muller C. D., Allison A. C. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scandinavian Journal of Immunology 1991; 33: 161
   PubMed Web of Science ®Google Scholar
• Zeevi A., Woan M., Yao G.-Z., Venkataramanan R., Todo S., Starzl T. E., Duquesnoy R. J. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. Transplantation Proceedings 1991; 23: 2928
   PubMedGoogle Scholar
• Platz K. P., Sollinger H. W., Hullett D. A., Eckhoff D. E., Eugui E. M., Allison A. C. RS-61443 - A new, potent immunosuppressive agent. Transplantation 1991; 51: 27
   PubMed Web of Science ®Google Scholar
• Zeevi A., Duquesnoy R., Eiras G., Rabinowich H., Todo S., Makowka L., Starzl T. E. Immunosuppressive effect of FK-506 on invitro lymphocyte alloactivation: Synergism with cyclosporine A. Transplantation Proceedings 1987; 19: 40
   PubMed Web of Science ®Google Scholar
• Jiang H., Suguo H., Takahara S., Takano Y., Li D., Kameoka H., Moutabarrik A., Kokado Y., Ishibashi M., Okuyama A., Sonoda T. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. Transplantation Proceedings 1991; 23: 2933
   PubMedGoogle Scholar
• Vathsala A., Chou Ting-C., Kahan B. D. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. Transplantation 1990; 49: 463
   PubMedGoogle Scholar
• Siekierka J. J., Hung S. H. Y., Poe M., Lin C. S., Sigal N. H. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341: 755
   PubMed Web of Science ®Google Scholar
• Schreiber S. L., Crabtree G. R. The mechanism of action of cyclosporin A and FK506. Immunology Today 1992; 13: 136
   PubMedGoogle Scholar
• Erlanger B. F. Do we know the site of action of cyclosporin?. Immunology Today 1992; 13: 487
   PubMedGoogle Scholar
• Aiello F. B., Maggiano N., Larocca L. M., Piantelli M., Musiani P. Inhibitory effect of cyclosporin A on the OKT3-induced peripheral blood lymphocyte proliferation. Cellular Immunology 1986; 97: 131
   PubMedGoogle Scholar
• La Rocca R. V., Stein C. A., Myers C. I. Suramin: Prototype of a new generation of antitumor compounds. Cancer Cells 1992; 2: 106
   Google Scholar
• Minniti C. P., Maggi M., Helman L. J. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Research 1992; 52: 1830
   PubMedGoogle Scholar
• Van Corven E. J., Van Rijswijk A., Jalink K., Van Der Bend R. L., Van Blitterswijk W. J., Moolenaar W. H. Mitogenic action of lysophosphatidic acid and phosphatidic acid on fibroblasts. Dependence on acyl-chain length and inhibition by suramin. Biochemical Journal 1992; 281: 163
   PubMed Web of Science ®Google Scholar
• Chang S. Y., Yu D. S., Sherwood E. R., Kozlowski J. M., Lee C. Inhibitory effects of suramin on a human renal cell carcinoma line, causing a nephrogenic hepatic dysfunction. Journal of Urology 1992; 147: 1147
   PubMedGoogle Scholar